91345-52-7

Usage

Structure

A derivative of benzene with a bromoethyl group and three methyl groups attached to the benzene ring

Usage

Commonly used in organic synthesis as a reagent for the preparation of various pharmaceuticals and agrochemicals, as a precursor for the production of specialty chemicals, and in the manufacturing of dyes, pigments, and fragrances

Potential applications

May have applications in the field of materials science and as a building block for the synthesis of novel organic compounds.

Upstream product

• 6950-92-1 2-(2,4,6-trimethylphenyl)ethanol 
• 576-83-0 2,4,6-trimethylphenyl bromide 

Downstream Products

• 39231-51-1 1,4-dimesityl-butane 
• 5336-58-3 dimethyl-(2,4,6-trimethyl-phenethyl)-amine 
• 70860-52-5 1,1-Dimethyl-3-{3-[2-(2,4,6-trimethyl-phenyl)-ethoxy]-phenyl}-urea 

Relevant academic research and scientific papers

Synthesis and Biological Evaluation of Fentanyl Analogues Modified at Phenyl Groups with Alkyls

A series of fentanyl analogues modified at the phenyl group of the phenethyl with alkyl and/or hydroxyl and alkoxy, and the phenyl group in the anilido moiety replaced with benzyl or substituted benzyl, were synthesized. The in vitro opioid receptor functional activity of these compounds was evaluated by assessment of their ability to modulate forskolin-stimulated cAMP accumulation and by their ability to induce β-arrestin2 recruitment. Compound 12 is a potent μ-opioid (MOP) receptor agonist, a potent κ-opioid (KOP) receptor antagonist with weak β-arrestin2 recruitment activity. Compounds 10 and 11 are potent MOP receptor agonists with weak δ-opioid (DOP) receptor antagonist activity and moderate KOP receptor antagonist activity as well as weak β-arrestin2 recruitment activity at the MOP receptor. These compounds are promising leads for discovery of potent opioid analgesics with reduced side effects relative to clinically available strong opioid analgesics.

Fentanyl analogue and application thereof

The invention discloses a fentanyl analogue and application thereof. A general structural formula of a compound is as follows (described in the following description), wherein R1 is a hydrogen group,a methyl group, a hydroxyl group, a methoxyl group, a halogen and a cyano group, and R2 is a phenyl group, a benzyl group and 3,5-benzyldimethyl. The compound provided by the invention embodies the activating effect of a mu-opioid receptor and the recruitment function of weak beta-arrestin 2, and therefore, the compound can be used as an analgesic drug and can overcome the respiration inhibition effect caused by activating a beta-arrestin 2 signal pathway.